The endocannabinoid system: Role in glucose and energy metabolism

Pharmacological Research

Volumn 60, Issue 2, 2009, Pages 93-98

  Nogueiras, Ruben ^a,b   Diaz Arteaga, Adenis ^a,b   Lockie, Sarah H ^c   Velásquez, Douglas A ^a,b   Tschop, Johannes ^c   López, Miguel ^a,b   Cadwell, Charles C ^c   Diéguez, Carlos ^a,b   Tschöp, Matthias H ^c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Endocannabinoids; Glucose metabolism; Obesity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; ACYL COENZYME A DESATURASE; ADIPONECTIN; ANANDAMIDE; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CARNITINE ACETYLTRANSFERASE; ENDOCANNABINOID; ENOYL COENZYME A HYDRATASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PLACEBO; RIMONABANT; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; BRAIN TISSUE; CLINICAL TRIAL; DIET THERAPY; DRUG DOSE COMPARISON; ENERGY BALANCE; ENERGY METABOLISM; FATTY ACID SYNTHESIS; FOOD INTAKE; GASTROINTESTINAL TRACT; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER PARENCHYMA; LOW CALORY DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; SKELETAL MUSCLE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANIMALS; ENDOCANNABINOIDS; ENERGY METABOLISM; GLUCOSE; HUMANS;

EID: 67449111443     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.04.004     Document Type: Review

References (61)

1. Schenk S., Saberi M., and Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118 (2008) 2992-3002
2. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
3. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87 (1990) 1932-1936
4. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor cb1. Biochem J 312 (1995) 637-641 (Pt 2)
5. Pertwee R.G. Pharmacology of cannabinoid cb1 and cb2 receptors. Pharmacol Ther 74 (1997) 129-180
6. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid cb2 receptors. Science 310 (2005) 329-332
7. Nogueiras R., Rohner-Jeanrenaud F., Woods S.C., and Tschop M.H. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 20 Suppl. 1 (2008) 147-151
8. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51 (2008) 1356-1367
9. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18 (2007) 27-37
10. Kunos G., Osei-Hyiaman D., Liu J., Godlewski G., and Batkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem 283 (2008) 33021-33025
11. Pagano C., Rossato M., and Vettor R. Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol 20 Suppl. 1 (2008) 124-129
12. Despres J.P., Golay A., and Sjostrom L. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
13. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of Rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: Rio-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
14. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker Rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the Rio-Europe study. Lancet 365 (2005) 1389-1397
15. Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. Efficacy and tolerability of Rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
16. Monteleone P., Matias I., Martiadis V., De Petrocellis L., Maj M., and Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30 (2005) 1216-1221
17. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
18. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91 (2006) 3171-3180
19. Tchernof A. Visceral adipocytes and the metabolic syndrome. Nutr Rev 65 (2007) S24-29
20. Bermudez-Silva F.J., Suarez J., Baixeras E., Cobo N., Bautista D., Cuesta-Munoz A.L., et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51 (2008) 476-487
21. Spoto B., Fezza F., Parlongo G., Battista N., Sgro E., Gasperi V., et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 88 (2006) 1889-1897
22. Bluher M., Engeli S., Kloting N., Berndt J., Fasshauer M., Batkai S., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-3060
23. Pagano C., Pilon C., Calcagno A., Urbanet R., Rossato M., Milan G., et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92 (2007) 4810-4819
24. Lofgren P., Sjolin E., Wahlen K., and Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 92 (2007) 1555-1559
25. Cavuoto P., McAinch A.J., Hatzinikolas G., Cameron-Smith D., and Wittert G.A. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267 (2007) 63-69
26. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovska A., Game P., and Wittert G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364 (2007) 105-110
27. Bermudez-Siva F.J., Serrano A., Diaz-Molina F.J., Sanchez Vera I., Juan-Pico P., Nadal A., et al. Activation of cannabinoid cb1 receptors induces glucose intolerance in rats. Eur J Pharmacol 531 (2006) 282-284
28. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
29. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., et al. The cb1 receptor antagonist Rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19 (2005) 1567-1569
30. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., and Soubrie P. Cb1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28 (2004) 640-648
31. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., et al. Anti-obesity effect of sr141716, a cb1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284 (2003) R345-353
32. Irwin N., Hunter K., Frizzell N., and Flatt P.R. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (cb1) antagonist, am251, in obese diabetic (ob/ob) mice. Eur J Pharmacol 581 (2008) 226-233
33. Nogueiras R., Veyrat-Durebex C., Suchanek P.M., Klein M., Tschop J., Caldwell C., et al. Peripheral, but not central, cb1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57 (2008) 2977-2991
34. Bermudez-Silva F.J., Sanchez-Vera I., Suarez J., Serrano A., Fuentes E., Juan-Pico P., et al. Role of cannabinoid cb2 receptors in glucose homeostasis in rats. Eur J Pharmacol 565 (2007) 207-211
35. Juan-Pico P., Fuentes E., Bermudez-Silva F.J., Javier Diaz-Molina F., Ripoll C., Rodriguez de Fonseca F., et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39 (2006) 155-162
36. Starowicz K.M., Cristino L., Matias I., Capasso R., Racioppi A., Izzo A.A., et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16 (2008) 553-565
37. Gasperi V., Fezza F., Pasquariello N., Bari M., Oddi S., Agro A.F., et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64 (2007) 219-229
38. Badman M.K., and Flier J.S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 132 (2007) 2103-2115
39. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
40. Buettner C., Muse E.D., Cheng A., Chen L., Scherer T., Pocai A., et al. Leptin controls adipose tissue lipogenesis via central, stat3-independent mechanisms. Nat Med 14 (2008) 667-675
41. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to c1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
42. Combs T.P., Berg A.H., Obici S., Scherer P.E., and Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein acrp30. J Clin Invest 108 (2001) 1875-1881
43. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
44. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
45. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., et al. The cannabinoid cb1 receptor antagonist sr141716 increases acrp30 mrna expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
46. Gary-Bobo M., Elachouri G., Scatton B., Le Fur G., Oury-Donat F., and Bensaid M. The cannabinoid cb1 receptor antagonist Rimonabant (sr141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3t3 f442a preadipocytes. Mol Pharmacol 69 (2006) 471-478
47. Thornton-Jones Z.D., Kennett G.A., Benwell K.R., Revell D.F., Misra A., Sellwood D.M., et al. The cannabinoid cb1 receptor inverse agonist, Rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 84 (2006) 353-359
48. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., et al. Endocannabinoid activation at hepatic cb1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
49. Jeong W.I., Osei-Hyiaman D., Park O., Liu J., Batkai S., Mukhopadhyay P., et al. Paracrine activation of hepatic cb1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7 (2008) 227-235
50. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I., et al. Hepatic cb1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118 (2008) 3160-3169
51. Esposito I., Proto M.C., Gazzerro P., Laezza C., Miele C., Alberobello A.T., et al. The cannabinoid cb1 receptor antagonist Rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 74 (2008) 1678-1686
52. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid cb1 receptor antagonist sr141716 on oxygen consumption and soleus muscle glucose uptake in lep(ob)/lep(ob) mice. Int J Obes (Lond) 29 (2005) 183-187
53. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
54. Bifulco M., Malfitano A.M., Pisanti S., and Laezza C. Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 15 (2008) 391-408
55. Bifulco M., Laezza C., Gazzerro P., and Pentimalli F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion. Oncol Rep 17 (2007) 813-816 [Review]
56. Bifulco M., Grimaldi C., Gazzerro P., Pisanti S., Santoro A., and Rimonabant:. Just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71 (2007) 1445-1456
57. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148 (2006) 123-135
58. Bifulco M., and Di Marzo V. The endocannabinoid system as a target for the development of new drugs for cancer therapy. Recent Prog Med 94 (2003) 194-198
59. Bifulco M., and Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8 (2002) 547-550
60. Pavon F.J., Bilbao A., Hernandez-Folgado L., Cippitelli A., Jagerovic N., Abellan G., et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2 4-triazole-lh 21. Neuropharmacology 51 (2006) 358-366
61. Pavon F.J., Serrano A., Perez-Valero V., Jagerovic N., Hernandez-Folgado L., Bermudez-Silva F.J., et al. Central versus peripheral antagonism of cannabinoid cb1 receptor in obesity: effects of lh-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20 Suppl. 1 (2008) 116-123